1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Prince Pharmaceutical Co., Ltd.

Prince Pharmaceutical Co., Ltd.

TTPEX:6935
28.50
TWD
0.00
(0.00%)
1.11BMarket Cap
Prince Pharmaceutical Co., Ltd.
TPEX:6935
(Taipei Exchange)

Recent

price

28.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
TWD
7.71
8.95
13.16
21.26
22.48
18.88
28.58
- -
Revenue per Share
- -
-1.02
-0.25
1.54
0.46
-1.47
2.61
- -
Basic EPS, GAAP
-5.41
-5.66
0.03
2.14
0.01
0.77
1.93
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.16
0.25
- -
- -
Dividend per Share
16.96
16.71
16.5
18.02
21.19
19.54
22.2
23.07
Book Value per Share
16.93
16.64
16.44
17.98
21.16
19.52
22.19
23.06
Tangible Book Value per Share
32
33
34
34
34
37
37
37
Basic Weighted Avg Shares
250
296
441
713
753
690
1,056
- -
Sales/Revenue/Turnover
-3.73
-17.03
-0.25
9.52
3.41
-7.15
10.5
- -
Operating Margin (%)
14
28
46
52
59
62
62
- -
Depreciation Expense
- -
-34
-8
52
15
-54
96
- -
Net Income, GAAP
35.71
- -
- -
19.7
20.12
- -
8.04
- -
Effective Tax Rate (%)
- -
-11.43
-1.88
7.24
2.03
-7.76
9.12
- -
Profit Margin (%)
-106
28
74
112
179
130
251
283
Working Capital
102
409
486
455
424
390
354
339
LT Debt
620
611
603
658
774
722
839
872
Total Equity
- -
- -
- -
4.63
1.68
- -
8.31
- -
Return on Invested Capital (%)
- -
- -
- -
5
1.93
- -
8.6
- -
Return on Capital (%)
- -
-5.49
-1.37
8.18
2.14
-7.16
12.34
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
70
68
69
LT Borrowings
251
234
217
LT Finance Leases
120
120
122
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
38
38
Market Capitalization
939
1,163
1,115

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
402
561
694
Cash, Cash Equivalents & STI
77
153
225
Accounts Receivable, Net
123
168
128
Inventories
173
206
299
Total Current Liabilities
246
310
411
Payables & Accruals
- -
- -
- -
ST Debt
70
68
69
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
6.99%
16.15%
Free Cash Flow
- -
3,484.92%
152.57%
Net Income, GAAP
- -
-319.27%
-279.9%
Sales/Revenue/Turnover
- -
32.21%
53.07%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
690
2025
- -
- -
1,056
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.47
2025
- -
- -
2.61
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.25
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Prince Pharmaceutical Co., Ltd. (6935.TWO) manufactures active pharmaceutical ingredients, primarily vitamin B1 derivatives, and health food products. The company produces vitamin B1 APIs compliant with USP, JP, and JPC pharmacopoeias; health foods via OEM operations; and western medicines including formulations such as injections, tablets, capsules, ointments, and powders. It operates APIs production facilities in Hsinchu Industrial Park, food factories in Xinpu and additional sites in Hsinchu County, with headquarters in Huwei Township, Yunlin County, Taiwan; founded in 1962, it supplies products to Taiwan, Japan, Europe including Spain, South Korea, Singapore, and other markets. Certifications encompass PIC/S GMP, cGMP, ISO 9001, ISO 22000, HACCP, GMP, and TQF for its plants. Nanpao Group became a shareholder in 2016, marking a key ownership change; the company completed product development in 2017 and reported health food sales growth to NT$554 million in 2024 alongside western medicine revenues, reflecting sustained operations in its core segments.